Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mizuho Reiterates Buy Rating and $21 PT on Ironwood Pharmaceuticals (IRWD) Following 4Q16 Results
February 22, 2017 5:52 AM ESTMizuho Securities analyst Irina Koffler reiterates Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), as the company reported 2016 fourth quarter revenues and EPS figures above consensus.
Koffler comments, "4Q:16 beat was great but not surprising since consensus largely omitted a $15M milestone associated with regulatory approval in Japan: IRWD reported 4Q:16 revenues of $87.5M... More
Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
February 21, 2017 4:03 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.12), $0.12 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $87.46 million versus the consensus estimate of $77.34 million.
2017 Financial Guidance
Ironwood expects 2017 R&D expenses to be in the range of $145... More